Brooklyn, NY -- (SBWIRE) -- 03/23/2016 -- The report is compiled with the intent of providing an executive-level snapshot of the market's prevailing dynamics. It also presents refined growth forecasts pertaining to the market's future outlook.

The report provides insights into the growth drivers and restraints impacting the growth trajectory of the India market for type 2 diabetes mellitus therapeutics. Type 2 diabetes mellitus is a long-term metabolic disorder characterized mainly by insulin resistance, relative lack of insulin, and high blood sugar. The most common symptoms of this ailment may include increased hunger and sores that do not heal. People suffering from type 2 diabetes mellitus may also complain of feeling easily tired. While in most cases the symptoms may come slowly, long-term complications related to high blood sugar can result in heart diseases, stroke, kidney failure, blindness, and poor blood flow to the limbs, leading to amputations.

To Get Sample Copy of Report visit @ http://www.qyresearchreports.com/sample/sample.php?rep_id=640600&type=E

The rising incidence of diabetes is mostly attributed to the increasing prevalence of obesity and lack of proper exercise. The resultant increase in the incidence of lifestyle disorders is anticipated to fuel the demand for type 2 diabetes mellitus therapeutics. The report provides a comprehensive overview of the India market for diabetes mellitus therapeutics, covering information pertaining to diabetes epidemiology, research and development pipeline, cost of therapy, and promising molecules.

The report also includes a comprehensive analysis of the type 2 diabetes pipeline and the available therapeutics for its treatment. Compiled with the intent of updating stakeholders about the prevailing market trends and factors influencing them, the report covers pertinent information about the market obtained from trusted industrial sources. Relevant data has been sourced through in-depth primary and secondary research methodologies. Valuable insights from industry veterans are also included in the report.

The report includes exhaustive information pertaining to the market's present dynamics and the growth trajectory it exhibits. Information thus compiled is presented in a coherent chapter-wise format interspersed with relevant graphs, info graphics, and statistics.

Browse Complete Report with Table of Content @ http://www.qyresearchreports.com/report/india-type-2-diabetes-mellitus-therapeutics-industry-2016-market-research-report.htm

To present a holistic overview of the market for diabetes mellitus therapeutics in India, the report also explores its competitive landscape. It profiles the leading companies operating in the market such as AstraZeneca, Novartis, Novo Nordisk, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Merck, Sanofi, Takeda, GlaxoSmithKline (GSK), Johnson & Johnson, and Bayer. Using SWOT analysis, the report weighs out the strengths and weaknesses of these companies. The analysis also provides information pertaining to the threats and opportunities that these companies may face in the forthcoming years.
The effect of Porter's five forces on the overall operations in the market is also examined in the report in detail.

Related Reports:

- Global Type 2 Diabetes Mellitus Therapeutics Market 2016
- China Type 2 Diabetes Mellitus Therapeutics Market 2016
- United States Type 2 Diabetes Mellitus Therapeutics Industry 2015